API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Vivacitas' lead development candidate (AR-67) is a novel lipophilic next-generation camptothecin (Topiosomerase-1 enzyme inhibitor) compound with the potential to deliver improved efficacy and tolerability, employing a proprietary synthesis method.
Lead Product(s): Silatecan
Therapeutic Area: Oncology Product Name: AR-67
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: DSS Biomedical International
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Financing August 02, 2021
Details:
The companies are collaborating to apply Artificial Intelligence (AI) technology and advanced imaging strategies to further the development of AR-67, a third generation Camptothecin, in patients with recurrent glioblastoma multiforme (reGBM).
Lead Product(s): Silatecan
Therapeutic Area: Oncology Product Name: AR-67
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Vivacitas Oncology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 03, 2021